2017
Epidemiologic factors that predict long-term survival following a diagnosis of epithelial ovarian cancer
Kim SJ, Rosen B, Fan I, Ivanova A, McLaughlin JR, Risch H, Narod SA, Kotsopoulos J. Epidemiologic factors that predict long-term survival following a diagnosis of epithelial ovarian cancer. British Journal Of Cancer 2017, 116: 964-971. PMID: 28208158, PMCID: PMC5379147, DOI: 10.1038/bjc.2017.35.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinoma, Clear CellAdenocarcinoma, MucinousAdultAgedCanadaCystadenocarcinoma, SerousEndometrial NeoplasmsEpidemiologic FactorsFemaleFollow-Up StudiesHormone Replacement TherapyHumansMiddle AgedNeoplasm InvasivenessNeoplasm StagingOvarian NeoplasmsParityPregnancyPrognosisReproductive HistoryYoung AdultConceptsOvarian cancer-specific mortalityCancer-specific mortalityHormone replacement therapyRisk of deathEpithelial ovarian cancerOvarian cancerHazard ratioEpidemiologic factorsOvulatory cyclesOvarian cancer-specific deathOvarian cancer-specific survivalInvasive epithelial ovarian cancerBMI 5 yearsCancer-specific survivalCancer-specific deathOntario Cancer RegistryProportional hazards regressionConfidence intervalsBorderline significant associationOvarian cancer developmentLong-term survivalGreater cumulative numberHRT useCancer RegistryHistologic subtype
2015
BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers
Meeks HD, Song H, Michailidou K, Bolla MK, Dennis J, Wang Q, Barrowdale D, Frost D, EMBRACE, McGuffog L, Ellis S, Feng B, Buys S, Hopper J, Southey M, Tesoriero A, Investigators K, James P, Bruinsma F, Campbell I, Group A, Broeks A, Schmidt M, Hogervorst F, HEBON, Beckman M, Fasching P, Fletcher O, Johnson N, Sawyer E, Riboli E, Banerjee S, Menon U, Tomlinson I, Burwinkel B, Hamann U, Marme F, Rudolph A, Janavicius R, Tihomirova L, Tung N, Garber J, Cramer D, Terry K, Poole E, Tworoger S, Dorfling C, van Rensburg E, Godwin A, Guénel P, Truong T, Collaborators G, Stoppa-Lyonnet D, Damiola F, Mazoyer S, Sinilnikova O, Isaacs C, Maugard C, Bojesen S, Flyger H, Gerdes A, Hansen T, Jensen A, Kjaer S, Hogdall C, Hogdall E, Pedersen I, Thomassen M, Benitez J, González-Neira A, Osorio A, de la Hoya M, Segura P, Diez O, Lazaro C, Brunet J, Anton-Culver H, Eunjung L, John E, Neuhausen S, Ding Y, Castillo D, Weitzel J, Ganz P, Nussbaum R, Chan S, Karlan B, Lester J, Wu A, Gayther S, Ramus S, Sieh W, Whittermore A, Monteiro A, Phelan C, Terry M, Piedmonte M, Offit K, Robson M, Levine D, Moysich K, Cannioto R, Olson S, Daly M, Nathanson K, Domchek S, Lu K, Liang D, Hildebrant M, Ness R, Modugno F, Pearce L, Goodman M, Thompson P, Brenner H, Butterbach K, Meindl A, Hahnen E, Wappenschmidt B, Brauch H, Brüning T, Blomqvist C, Khan S, Nevanlinna H, Pelttari L, Aittomäki K, Butzow R, Bogdanova N, Dörk T, Lindblom A, Margolin S, Rantala J, Kosma V, Mannermaa A, Lambrechts D, Neven P, Claes K, Van Maerken T, Chang-Claude J, Flesch-Janys D, Heitz F, Varon-Mateeva R, Peterlongo P, Radice P, Viel A, Barile M, Peissel B, Manoukian S, Montagna M, Oliani C, Peixoto A, Teixeira M, Collavoli A, Hallberg E, Olson J, Goode E, Hart S, Shimelis H, Cunningham J, Giles G, Milne R, Healey S, Tucker K, Haiman C, Henderson B, Goldberg M, Tischkowitz M, Simard J, Soucy P, Eccles D, Le N, Borresen-Dale A, Kristensen V, Salvesen H, Bjorge L, Bandera E, Risch H, Zheng W, Beeghly-Fadiel A, Cai H, Pylkäs K, Tollenaar R, van der Ouweland A, Andrulis I, Knight J, OCGN, Narod S, Devilee P, Winqvist R, Figueroa J, Greene M, L. P, Loud J, García-Closas M, Schoemaker M, Czene K, Darabi H, McNeish I, Siddiquil N, Glasspool R, Kwong A, Park S, Teo S, Yoon S, Matsuo K, Hosono S, Woo Y, Gao Y, Foretova L, Singer C, Rappaport-Feurhauser C, Friedman E, Laitman Y, Rennert G, Imyanitov E, Hulick P, Olopade O, Senter L, Olah E, Doherty J, Schildkraut J, Koppert L, Kiemeney L, Massuger L, Cook L, Pejovic T, Li J, Borg A, Öfverholm A, Rossing M, Wentzensen N, Henriksson K, Cox A, Cross S, Pasini B, Shah M, Kabisch M, Torres D, Jakubowska A, Lubinski J, Gronwald J, Agnarsson B, Kupryjanczyk J, Moes-Sosnowska J, Fostira F, Konstantopoulou I, Slager S, Jones M, in the genome P, Antoniou A, Berchuck A, Swerdlow A, Chenevix-Trench G, Dunning A, Pharoah P, Hall P, Easton D, Couch F, Spurdle A, Goldgar D. BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. Journal Of The National Cancer Institute 2015, 108: djv315. PMID: 26586665, PMCID: PMC4907358, DOI: 10.1093/jnci/djv315.Peer-Reviewed Original ResearchConceptsOvarian cancerBreast cancerVariant carriersCancer riskEstrogen receptor-negative breast cancerReceptor-negative breast cancerCancer case patientsInvasive ovarian cancerHormone-related cancersProstate cancer riskConfidence intervalsOvarian cancer riskSignificant inverse associationCox proportional hazardsSerous ovarian cancerRisk of breastBRCA1 mutation carriersPathogenic BRCA2 variantsControl patientsCase patientsInverse associationOdds ratioProstate cancerMutation carriersProportional hazards
2013
Type I and II Endometrial Cancers: Have They Different Risk Factors?
Setiawan VW, Yang HP, Pike MC, McCann SE, Yu H, Xiang YB, Wolk A, Wentzensen N, Weiss NS, Webb PM, van den Brandt PA, van de Vijver K, Thompson PJ, Group T, Strom BL, Spurdle AB, Soslow RA, Shu XO, Schairer C, Sacerdote C, Rohan TE, Robien K, Risch HA, Ricceri F, Rebbeck TR, Rastogi R, Prescott J, Polidoro S, Park Y, Olson SH, Moysich KB, Miller AB, McCullough ML, Matsuno RK, Magliocco AM, Lurie G, Lu L, Lissowska J, Liang X, Lacey JV, Kolonel LN, Henderson BE, Hankinson SE, Håkansson N, Goodman MT, Gaudet MM, Garcia-Closas M, Friedenreich CM, Freudenheim JL, Doherty J, De Vivo I, Courneya KS, Cook LS, Chen C, Cerhan JR, Cai H, Brinton LA, Bernstein L, Anderson KE, Anton-Culver H, Schouten LJ, Horn-Ross PL. Type I and II Endometrial Cancers: Have They Different Risk Factors? Journal Of Clinical Oncology 2013, 31: 2607-2618. PMID: 23733771, PMCID: PMC3699726, DOI: 10.1200/jco.2012.48.2596.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAge FactorsAgedBiopsy, NeedleCarcinoma, EndometrioidCase-Control StudiesCohort StudiesConfidence IntervalsContraceptives, OralDatabases, FactualDiabetes MellitusDisease-Free SurvivalEndometrial NeoplasmsFemaleHumansImmunohistochemistryMiddle AgedNeoplasm InvasivenessNeoplasm StagingObesityOdds RatioRisk FactorsSensitivity and SpecificitySmokingSurvival AnalysisConceptsType II tumorsII tumorsRisk factorsEndometrial cancerOdds ratioHigh-grade endometrioid tumorsEndometrial cancer risk factorsType IEndometrial Cancer ConsortiumEndometrial cancer typesType I tumorsEndometrial cancer casesOral contraceptive useRisk factor patternsBody mass indexCancer risk factorsCommon etiologic factorCase-control studyDifferent risk factorsEndometrioid tumorsI tumorsMass indexCigarette smokingPooled analysisEtiologic factorsGWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer
Pharoah PD, Tsai YY, Ramus SJ, Phelan CM, Goode EL, Lawrenson K, Buckley M, Fridley BL, Tyrer JP, Shen H, Weber R, Karevan R, Larson MC, Song H, Tessier DC, Bacot F, Vincent D, Cunningham JM, Dennis J, Dicks E, Aben K, Anton-Culver H, Antonenkova N, Armasu S, Baglietto L, Bandera E, Beckmann M, Birrer M, Bloom G, Bogdanova N, Brenton J, Brinton L, Brooks-Wilson A, Brown R, Butzow R, Campbell I, Carney M, Carvalho R, Chang-Claude J, Chen Y, Chen Z, Chow W, Cicek M, Coetzee G, Cook L, Cramer D, Cybulski C, Dansonka-Mieszkowska A, Despierre E, Doherty J, Dörk T, du Bois A, Dürst M, Eccles D, Edwards R, Ekici A, Fasching P, Fenstermacher D, Flanagan J, Gao Y, Garcia-Closas M, Gentry-Maharaj A, Giles G, Gjyshi A, Gore M, Gronwald J, Guo Q, Halle M, Harter P, Hein A, Heitz F, Hillemanns P, Hoatlin M, Høgdall E, Høgdall C, Hosono S, Jakubowska A, Jensen A, Kalli K, Karlan B, Kelemen L, Kiemeney L, Kjaer S, Konecny G, Krakstad C, Kupryjanczyk J, Lambrechts D, Lambrechts S, Le N, Lee N, Lee J, Leminen A, Lim B, Lissowska J, Lubiński J, Lundvall L, Lurie G, Massuger L, Matsuo K, McGuire V, McLaughlin J, Menon U, Modugno F, Moysich K, Nakanishi T, Narod S, Ness R, Nevanlinna H, Nickels S, Noushmehr H, Odunsi K, Olson S, Orlow I, Paul J, Pejovic T, Pelttari L, Permuth-Wey J, Pike M, Poole E, Qu X, Risch H, Rodriguez-Rodriguez L, Rossing M, Rudolph A, Runnebaum I, Rzepecka I, Salvesen H, Schwaab I, Severi G, Shen H, Shridhar V, Shu X, Sieh W, Southey M, Spellman P, Tajima K, Teo S, Terry K, Thompson P, Timorek A, Tworoger S, van Altena A, van den Berg D, Vergote I, Vierkant R, Vitonis A, Wang-Gohrke S, Wentzensen N, Whittemore A, Wik E, Winterhoff B, Woo Y, Wu A, Yang H, Zheng W, Ziogas A, Zulkifli F, Goodman M, Hall P, Easton D, Pearce C, Berchuck A, Chenevix-Trench G, Iversen E, Monteiro A, Gayther S, Schildkraut J, Sellers T. GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nature Genetics 2013, 45: 362-370. PMID: 23535730, PMCID: PMC3693183, DOI: 10.1038/ng.2564.Peer-Reviewed Original ResearchMeSH KeywordsCase-Control StudiesCooperative BehaviorCystadenocarcinoma, SerousFemaleGene-Environment InteractionGenetic LociGenetic Predisposition to DiseaseGenome-Wide Association StudyGenotypeHumansMeta-Analysis as TopicNeoplasm InvasivenessOvarian NeoplasmsPolymorphism, Single NucleotideRisk FactorsConceptsOvarian cancer susceptibility lociSusceptibility lociGenome-wide association studiesNew susceptibility lociCancer susceptibility lociRegulatory regionsAssociation studiesMolecular analysisLociDisease mechanismsOvarian Cancer Association ConsortiumOvarian cancerGWASGenesEpithelial ovarian cancerConsortiumLong-Term Ovarian Cancer Survival Associated With Mutation in BRCA1 or BRCA2
McLaughlin JR, Rosen B, Moody J, Pal T, Fan I, Shaw PA, Risch HA, Sellers TA, Sun P, Narod SA. Long-Term Ovarian Cancer Survival Associated With Mutation in BRCA1 or BRCA2. Journal Of The National Cancer Institute 2013, 105: 141-148. PMID: 23257159, PMCID: PMC3611851, DOI: 10.1093/jnci/djs494.Peer-Reviewed Original ResearchConceptsInvasive ovarian cancerOvarian cancerBRCA2 mutationsLong-term survival benefitOvarian cancer-specific survivalCancer-specific survivalOvarian cancer survivalSerous ovarian cancerShort-term survival advantageBRCA1 mutation carriersLong-term survivalHazard ratioSurvival benefitBetter prognosisUnselected womenBRCA2 carriersCancer survivalMutation carriersSurvival advantageSurvival analysisCancerDiagnosisTime pointsWomenSurvival
2012
Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case–control studies
Pearce CL, Templeman C, Rossing MA, Lee A, Near AM, Webb PM, Nagle CM, Doherty JA, Cushing-Haugen KL, Wicklund KG, Chang-Claude J, Hein R, Lurie G, Wilkens LR, Carney ME, Goodman MT, Moysich K, Kjaer SK, Hogdall E, Jensen A, Goode EL, Fridley BL, Larson MC, Schildkraut JM, Palmieri RT, Cramer DW, Terry KL, Vitonis AF, Titus LJ, Ziogas A, Brewster W, Anton-Culver H, Gentry-Maharaj A, Ramus SJ, Anderson AR, Brueggmann D, Fasching PA, Gayther SA, Huntsman DG, Menon U, Ness RB, Pike MC, Risch H, Wu AH, Berchuck A, Consortium O. Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case–control studies. The Lancet Oncology 2012, 13: 385-394. PMID: 22361336, PMCID: PMC3664011, DOI: 10.1016/s1470-2045(11)70404-1.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overCase-Control StudiesEndometriosisEthnicityFemaleHumansMiddle AgedNeoplasm InvasivenessNeoplasm StagingOvarian NeoplasmsRisk FactorsConceptsInvasive ovarian cancerSelf-reported endometriosisHistory of endometriosisCase-control studyHistological subtypesOvarian cancerBorderline tumorsOvarian cancer case-control studiesOral contraceptive useBorderline ovarian cancerSubset of womenEpithelial ovarian cancerDanish Cancer SocietyCancer case-control studyOvarian Cancer Association ConsortiumUK National InstituteNational InstituteLogistic regression analysisCancer Research FundCancer Research ProgramMedical Research CouncilCancer Research CenterUS Army Medical ResearchInvasive casesPooled analysis
2011
The Role of KRAS rs61764370 in Invasive Epithelial Ovarian Cancer: Implications for Clinical Testing
Pharoah PD, Palmieri RT, Ramus SJ, Gayther SA, Andrulis IL, Anton-Culver H, Antonenkova N, Antoniou AC, Goldgar D, Investigators F, Beattie MS, Beckmann MW, Birrer MJ, Bogdanova N, Bolton KL, Brewster W, Brooks-Wilson A, Brown R, Butzow R, Caldes T, Caligo MA, Campbell I, Chang-Claude J, Chen YA, Cook LS, Couch FJ, Cramer DW, Cunningham JM, Despierre E, Doherty JA, Dörk T, Dürst M, Eccles DM, Ekici AB, Easton D, Investigators F, Fasching PA, de Fazio A, Fenstermacher DA, Flanagan JM, Fridley BL, Friedman E, Gao B, Sinilnikova O, Collaborators F, Gentry-Maharaj A, Godwin AK, Goode EL, Goodman MT, Gross J, Hansen TV, Harnett P, Rookus M, Investigators F, Heikkinen T, Hein R, Høgdall C, Høgdall E, Iversen ES, Jakubowska A, Johnatty SE, Karlan BY, Kauff ND, Kaye SB, Chenevix-Trench G, Investigators and the Consortium of Investigators of Modifiers of BRCA1/2 F, Kelemen LE, Kiemeney LA, Kjaer SK, Lambrechts D, LaPolla JP, Lázaro C, Le ND, Leminen A, Leunen K, Levine DA, Lu Y, Lundvall L, Macgregor S, Marees T, Massuger LF, McLaughlin JR, Menon U, Montagna M, Moysich KB, Narod SA, Nathanson KL, Nedergaard L, Ness RB, Nevanlinna H, Nickels S, Osorio A, Paul J, Pearce CL, Phelan CM, Pike MC, Radice P, Rossing MA, Schildkraut JM, Sellers TA, Singer CF, Song H, Stram DO, Sutphen R, Lindblom A, Investigators F, Terry KL, Tsai YY, van Altena AM, Vergote I, Vierkant RA, Vitonis AF, Walsh C, Wang-Gohrke S, Wappenschmidt B, Wu AH, Ziogas A, Berchuck A, Risch HA, Consortium F. The Role of KRAS rs61764370 in Invasive Epithelial Ovarian Cancer: Implications for Clinical Testing. Clinical Cancer Research 2011, 17: 3742-3750. PMID: 21385923, PMCID: PMC3107901, DOI: 10.1158/1078-0432.ccr-10-3405.Peer-Reviewed Original ResearchMeSH Keywords3' Untranslated RegionsCarcinoma, Ovarian EpithelialDisease-Free SurvivalEarly Detection of CancerFemaleGenes, BRCA1Genetic Predisposition to DiseaseGenotypeHumansMicroRNAsNeoplasm InvasivenessNeoplasms, Glandular and EpithelialOvarian NeoplasmsPolymorphism, Single NucleotideProto-Oncogene ProteinsProto-Oncogene Proteins p21(ras)Ras ProteinsRiskConceptsOvarian cancerSingle nucleotide polymorphismsOvarian cancer risk evaluationProgression-free survival dataInvasive epithelial ovarian cancerEpithelial ovarian cancerOvarian Cancer Association ConsortiumCause mortality dataModifiers of BRCA1/2Familial ovarian cancerCancer risk evaluationClinical risk predictionConsortium of InvestigatorsOvarian cancer susceptibilityEvidence of associationInvasive EOCSerous EOCFamily historyUnselected casesSurvival timeRisk associationClinical testingKRAS oncogeneClinical testsSerous casesFrequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer
Zhang S, Royer R, Li S, McLaughlin JR, Rosen B, Risch HA, Fan I, Bradley L, Shaw PA, Narod SA. Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer. Gynecologic Oncology 2011, 121: 353-357. PMID: 21324516, DOI: 10.1016/j.ygyno.2011.01.020.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsAgedFemaleGenes, BRCA1Genes, BRCA2Germ-Line MutationHumansMiddle AgedNeoplasm InvasivenessOntarioOvarian NeoplasmsPrevalenceYoung AdultConceptsInvasive ovarian cancerOvarian cancerFirst-degree relativesMultiplex ligation-dependent probe amplificationUnselected patientsBRCA2 mutationsNon-mucinous ovarian cancerGermline mutationsCombined mutation frequencyPopulation-based seriesOvarian cancer patientsCommon adult cancersSerous ovarian cancerPrevalence of mutationsFrequency of BRCA1Mucinous carcinomaCancer patientsAdult cancersLigation-dependent probe amplificationCancerGenetic testingPatientsWomenBreastBRCA1
2008
Progesterone receptor variation and risk of ovarian cancer is limited to the invasive endometrioid subtype: results from the ovarian cancer association consortium pooled analysis
Pearce CL, Wu AH, Gayther SA, Bale AE, Beck P, Beesley J, Chanock S, Cramer D, DiCioccio R, Edwards R, Fredericksen Z, Garcia-Closas M, Goode E, Green A, Hartmann L, Hogdall E, Kjær S, Lissowska J, McGuire V, Modugno F, Moysich K, Ness R, Ramus S, Risch H, Sellers T, Song H, Stram D, Terry K, Webb P, Whiteman D, Whittemore A, Zheng W, Pharoah P, Chenevix-Trench G, Pike M, Schildkraut J, Berchuck A, on behalf of the Ovarian Cancer Association Consortium (OCAC). Progesterone receptor variation and risk of ovarian cancer is limited to the invasive endometrioid subtype: results from the ovarian cancer association consortium pooled analysis. British Journal Of Cancer 2008, 98: 282-288. PMID: 18219286, PMCID: PMC2361465, DOI: 10.1038/sj.bjc.6604170.Peer-Reviewed Original ResearchConceptsEndometrioid ovarian cancerOvarian cancer riskProgesterone receptor geneCase-control studyOvarian cancerCancer riskSingle nucleotide polymorphismsPGR single-nucleotide polymorphismInvasive epithelial ovarian cancerOvarian cancer case-control studiesEpithelial ovarian cancerUnconditional logistic regressionCancer case-control studyOvarian cancer casesOvarian Cancer Association ConsortiumTwo-sided p valueEndometrioid subtypePROGINS alleleCancer casesBorderline evidencePROGINS variantSubtype analysisSignificant associationT variantCancer